rs397515363
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_012144.4(DNAI1):c.48+2dup variant causes a splice donor change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000603 in 1,613,910 control chromosomes in the GnomAD database, with no homozygous occurrence. 1/1 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.00044 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00062 ( 0 hom. )
Consequence
DNAI1
NM_012144.4 splice_donor
NM_012144.4 splice_donor
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 3.29
Genes affected
DNAI1 (HGNC:2954): (dynein axonemal intermediate chain 1) This gene encodes a member of the dynein intermediate chain family. The encoded protein is part of the dynein complex in respiratory cilia. The inner- and outer-arm dyneins, which bridge between the doublet microtubules in axonemes, are the force-generating proteins responsible for the sliding movement in axonemes. The intermediate and light chains, thought to form the base of the dynein arm, help mediate attachment and may also participate in regulating dynein activity. Mutations in this gene result in abnormal ciliary ultrastructure and function associated with primary ciliary dyskinesia and Kartagener syndrome. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2013]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PVS1
Splicing +-2 bp (donor or acceptor) variant, product NOT destroyed by NMD, known LOF gene, truncates exone, which is 0.11809524 fraction of the gene. Cryptic splice site detected, with MaxEntScore 6.6, offset of 6, new splice context is: aacGTacgc. Cryptic site results in inframe change. If cryptic site found is not functional and variant results in exon loss, it results in inframe change.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 9-34459054-G-GT is Pathogenic according to our data. Variant chr9-34459054-G-GT is described in ClinVar as [Pathogenic]. Clinvar id is 5604.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
DNAI1 | NM_012144.4 | c.48+2dup | splice_donor_variant | ENST00000242317.9 | NP_036276.1 | |||
DNAI1 | NM_001281428.2 | c.48+2dup | splice_donor_variant | NP_001268357.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
DNAI1 | ENST00000242317.9 | c.48+2dup | splice_donor_variant | 1 | NM_012144.4 | ENSP00000242317 | ||||
DNAI1 | ENST00000437363.5 | c.48+2dup | splice_donor_variant | 5 | ENSP00000395396 | |||||
DNAI1 | ENST00000614641.4 | c.48+2dup | splice_donor_variant | 5 | ENSP00000480538 | P1 | ||||
DNAI1 | ENST00000470982.5 | n.47+1595dup | intron_variant, non_coding_transcript_variant | 5 |
Frequencies
GnomAD3 genomes AF: 0.000440 AC: 67AN: 152182Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
67
AN:
152182
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000402 AC: 101AN: 251308Hom.: 1 AF XY: 0.000309 AC XY: 42AN XY: 135854
GnomAD3 exomes
AF:
AC:
101
AN:
251308
Hom.:
AF XY:
AC XY:
42
AN XY:
135854
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000620 AC: 906AN: 1461610Hom.: 0 Cov.: 30 AF XY: 0.000568 AC XY: 413AN XY: 727118
GnomAD4 exome
AF:
AC:
906
AN:
1461610
Hom.:
Cov.:
30
AF XY:
AC XY:
413
AN XY:
727118
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000440 AC: 67AN: 152300Hom.: 0 Cov.: 32 AF XY: 0.000416 AC XY: 31AN XY: 74470
GnomAD4 genome
AF:
AC:
67
AN:
152300
Hom.:
Cov.:
32
AF XY:
AC XY:
31
AN XY:
74470
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:21Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:8
Pathogenic, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, Amsterdam University Medical Center | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC) | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Sep 28, 2021 | This sequence change has been described in the gnomAD database with a frequency of 0.073% in the non-Finnish European subpopulation (dbSNP rs1435805945). This sequence change has previously been described in several individuals with DNAI1-related primary ciliary dyskinesia in both homozygous and compound heterozygous state (PMIDs: 16858015, 33131162, 10577904, and 18434704). Functional studies showed that this 1-bp insertion impacts RNA splicing (PMID: 10577904. c.48+2dup is a common founder mutation in primary ciliary dyskinesia (PMID: 16858015) and is also reported with alternative nomenclatures such as c.48+2_48+3insT and IVS+2_3insT in the literature. - |
Pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Sep 26, 2014 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Feb 07, 2022 | Canonical splice site variant demonstrated to result in loss-of-function (Pennarun et al., 1999) in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 20301301, 23477994, 11231901, 10577904, 26918822, 29363216, 18434704, 30290127, 16858015, 31772028, 31879361, 31980526, 33131162, 33726816, 27535533) - |
Kartagener syndrome Pathogenic:6Other:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 02, 2022 | - - |
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Genomics England Pilot Project, Genomics England | - | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Dec 01, 1999 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Johns Hopkins Genomics, Johns Hopkins University | May 22, 2023 | This DNAI1 canonical splice variant has been reported in many individuals with primary ciliary dyskinesia 1. This variant (rs1435805945) is rare (<0.1%) in a large population dataset (gnomAD v2.1.1: 113/282694 total alleles; 0.04%; 1 homozygote), and has been reported in ClinVar4 (Variation ID 5604). This variant destroys a canonical donor site, is predicted to cause abnormal gene splicing and has supporting functional evidence. We consider c.48+2dup in DNAI1 to be pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Dec 14, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein | Sep 21, 2022 | ACMG classification criteria: PVS1 strong, PS3 supporting, PM2 moderated, PM3 very strong - |
Primary ciliary dyskinesia Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | UNC Molecular Genetics Laboratory, University of North Carolina at Chapel Hill | Oct 02, 2020 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 27, 2024 | This sequence change falls in intron 1 of the DNAI1 gene. It does not directly change the encoded amino acid sequence of the DNAI1 protein. RNA analysis indicates that this variant induces altered splicing and may result in an absent or disrupted protein product. This variant is present in population databases (rs755575751, gnomAD 0.07%), including at least one homozygous and/or hemizygous individual. This variant has been observed in individuals with primary ciliary dyskinesia (PMID: 10577904, 11231901, 16858015, 18434704). This variant is also known as c.48+2_48+3insT and IVS+2_3insT. ClinVar contains an entry for this variant (Variation ID: 5604). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant results in partial retention of intron 1 and introduces a premature termination codon (PMID: 10577904). The resulting mRNA is expected to undergo nonsense-mediated decay. For these reasons, this variant has been classified as Pathogenic. - |
Likely pathogenic, no assertion criteria provided | literature only | Yale Center for Mendelian Genomics, Yale University | Aug 01, 2018 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Aug 09, 2018 | The c.48+2dupT variant in DNAI1 is a well-known pathogenic founder variant (Zari wala 2006). It has been reported in >25 compound heterozygous or homozygous indi viduals with primary ciliary dyskinesia (PCD) with or without situs inversus (Ka rtagener syndrome) and segregated with disease in at least 2 affected relatives (Pennarun 1999, Guichard 2001, Zariwala 2006, Failly 2008, Li 2016, Paff 2018). This variant has been identified in 91/126580 European chromosomes, including on e homozygote, by the Genome Aggregation Database (gnomAD, http://gnomad.broadins titute.org; dbSNP rs397515363). This variant occurs in the invariant region (+/- 1,2) of the splice consensus sequence and is predicted to cause altered splicin g leading to an abnormal or absent protein. Functional studies provide some evid ence that this variant alters splicing, resulting in a truncated protein (Pennar un 1999, Zariwala 2006), and ultrastructural defects in the outer dynein arms we re observed in homozygous or compound heterozygous individuals (Guichard 2001, P aff 2018). In summary, this variant meets criteria to be classified as pathogeni c for primary ciliary dyskinesia in an autosomal recessive manner. ACMG/AMP Crit eria applied: PVS1_Strong, PM3_VeryStrong, PS3_Moderate, PP1. - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 06, 2014 | - - |
DNAI1-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | May 15, 2024 | The DNAI1 c.48+2dupT variant is predicted to result in an intronic duplication. This variant is a well-documented founder variant and known cause of autosomal recessive primary ciliary dyskinesia (PCD) and Kartagener syndrome (Pennarun et al. 1999. PubMed ID: 10577904; Zariwala et al. 2006. PubMed ID: 16858015; Failly et al. 2008. PubMed ID: 18434704). In the literature, this variant is also reported as IVS1+2_3insT or c.48+2_48+3insT. This variant is reported in 0.073% of alleles in individuals of European (Non-Finnish) descent in gnomAD. This variant is interpreted as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_DL_spliceai
Position offset: -1
Find out detailed SpliceAI scores and Pangolin per-transcript scores at